Skip to main content
OpenTrials
Completed

NCT Number: NCT01669590

Nutrient Regulation of Amino Acid Transporters in Aging Human Skeletal Muscle

The goal of the research project is to determine how aging and inactivity reduce the muscle anabolic effect of nutrients and lead to muscle and functional loss. The central hypothesis is that aging reduces mTORC1 signaling and the expression of skeletal muscle amino acid transporters in response to anabolic stimulation leading to reduced muscle adaptation to increased intracellular amino acid requirements. The investigators further hypothesize that inactivity exacerbates this effect with significant muscle and functional loss, and rehabilitation restores muscle signaling, metabolism and function to baseline values.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The University of Utah

Salt Lake City, Utah, 84112, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

1 . Age between 18-35 and 60-75 yrs 2. Ability to sign informed consent 3. Mini-mental state exam score >26 4. Free-living, prior to admission

Exclusion criteria

  • Cardiac abnormalities considered exclusionary by the study physician (e.g., CHF, CAD, right-to-left shunt)
  • Uncontrolled endocrine or metabolic disease (e.g., hypo/hyperthyroidism, diabetes)
  • GFR <65 mL/min/1.73m2 or evidence of kidney disease or failure
  • Vascular disease or risk factors of peripheral atherosclerosis. (e.g., uncontrolled hypertension, obesity, diabetes, hypercholesterolemia > 250 mg/dl, claudication or evidence of venous or arterial insufficiency upon palpitation of femoral, popliteal and pedal arteries)
  • Risk of DVT including family history of thrombophilia, DVT, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb>18 g/dL) or thrombocytosis (platelets>400x103/mL), and connective tissue diseases (positive lupus anticoagulant), hyperhomocysteinemia, deficiencies of factor V Leiden, proteins S and C, and antithrombin III
  • Use of anticoagulant therapy. (e.g., Coumadin, heparin)
  • Prior history of Heparin-Induced Thrombocytopenia (HIT)
  • Elevated systolic pressure >150 or a diastolic blood pressure > 100
  • Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators)
  • Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma
  • Currently on a weight-loss diet or body mass index > 30 kg/m2
  • Inability to abstain from smoking for duration of study
  • A history of > 20 pack per year smoking
  • HIV or hepatitis B or C*
  • Recent anabolic or corticosteroids use (within 3 months)
  • Subjects with hemoglobin or hematocrit lower than accepted lab values
  • Agitation/aggression disorder (by psychiatric history and exam)
  • History of stroke with motor disability
  • A recent history (<12 months) of GI bleed
  • Pregnancy as determined by a pregnancy test
  • Depression [>5 on the 15 items Geriatric Depression Scale (GDS)]
  • Alcohol or drug abuse
  • Exercise training (>1 session of moderate to high intensity aerobic or resistance exercise/week)
  • Liver disease (AST/ALT 2 times above the normal limit, hyperbilirubinemia)
  • Respiratory disease (acute upper respiratory infection, history of chronic lung disease with resting oxygen saturation <97% on room air)
  • Any other condition or event considered exclusionary by the PI and faculty physician

Treatment and study plan

Primary outcomes

  1. amino acid transporter

    Time frame: before and after (1 and 3h) amino acid ingestion. These samples will be taken before bed rest and 7 days after bed rest.

    Muscle biopsies will be sampled from the vastus laterals before amino acid ingestion and then 1 and 3h after amino acid ingestion. Muscle biopsies will be processed using western blotting and gene expression to assess the expression of specific amino acid transporters. The investigators are interested in the change in expression of amino acid transporters in response to amino acid ingestion from baseline. The response before bed rest will be compared to after bed rest.

Sponsors and collaborators

Lead sponsor

University of Utah

Other

Registry information

Important dates

Study start
2011
Primary completion
2016
Study completion
2016
First posted
Aug 21, 2012
Registry last updated
Nov 16, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.